| 产品描述: | RO-28-1675 is a potent allosteric glucokinase (GK) activator with an EC50 of 54 nM. RO-28-1675 can be used for the research of type 2 diabetes |
| 靶点: |
EC50: 54 nM (glucokinase) |
| 体外研究: |
RO-28-1675 can reverse the inhibitory action of the human glucokinase regulatory protein (GKRP) |
| 体内研究: |
RO-28-1675 (50 mg/kg; p.o.) reduces blood glucose levels in wild-type C57BL/6J mice[2]. RO-28-1675 exhibits high oral bioavailability (mice 92.8%) and Cmax (1140 μg/mL) following oral administration (10 mg/kg). Animal Model: 10 weeks old male C57BL/6J mice Dosage: 50 mg/kg Administration: Oral administration Result: Reduced blood glucose levels. Animal Model: C57BL/6J mice Dosage: 10 mg/kg (Pharmacokinetic Analysis Administration: Oral administration Result: Oral bioavailability (92.8%), Cmax (1140 μg/mL), T max (3.3 h). |
| 参考文献: |
1. Nancy-Ellen Haynes, et al. Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675). J Med Chem. 2010 May 13;53(9):3618-25. 2. Joseph Grimsby, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science. 2003 Jul 18;301(5631):370-3. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.642 ml |
13.21 ml |
26.419 ml |
| 5 mM |
0.528 ml |
2.642 ml |
5.284 ml |
| 10 mM |
0.264 ml |
1.321 ml |
2.642 ml |
| 50 mM |
0.053 ml |
0.264 ml |
0.528 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |